How Pancreatic Cancer Rewrites Its DNA to Resist Treatment and Spread
Researchers at NYU Langone Health and its Perlmutter Cancer Center examined 443,451 individual pancreatic ductal adenocarcinoma cells across 62 tumors, uncovering how the disease continually rewrites its genetic material to evade treatment and spread through the body. Published October 13 in Nature Genetics, the study reveals new details about how pancreatic cancer constantly changes its genetic makeup, explaining why nearly 85 percent of patients die within five years of diagnosis.
- Blocking the hyperactive MYC gene in laboratory experiments forced aggressive basal pancreatic cancer cells back into a less aggressive classical state.
- Clones exhibited high TIGIT and low PD1 gene activity, pointing to specific pathways tumors use to hide from immune system detection.
Mapping Cellular Diversity Across 443,451 Individual Cells
Traditional diagnostic methods typically measure gene activity across large, aggregated groups of cancer cells, which obscures the nuanced behaviors of smaller cell populations. By shifting to single-cell transcriptomics, the research team mapped the complex pathogenesis of pancreatic ductal adenocarcinoma at unprecedented resolution. The investigation utilized samples from 56 patients, including six individuals who provided paired biopsies both before and after undergoing chemotherapy.
Each clone shares foundational genetic markers yet exhibits divergent functional traits. Certain clones develop DNA alterations that withstand chemotherapeutic agents, while others specialize in invading adjacent stroma and metastasizing to distant organs. The investigation noted that these ongoing modifications mean the tumor functions as a moving target, continuously adapting rather than relying on a fixed set of static mutations.
MYC Gene Drives Aggressive Tumor Behavior
The investigation isolated the MYC gene as a primary driver of aggressive tumor behavior. Investigators observed heightened MYC activity specifically within the most virulent cell populations. When researchers blocked MYC activity in laboratory experiments involving aggressive basal pancreatic cancer cells, the cells reverted toward a less aggressive classical state.
Beyond tumor plasticity, the data illuminated why immunotherapies targeting the PD1 protein often display limited efficacy in clinical settings. Certain cancer clones displayed elevated activity of the TIGIT gene paired with reduced PD1 expression, effectively establishing a molecular shield against immune detection.
Next Steps in Clinical Research
While laboratory experiments successfully forced aggressive cells into less dangerous states by inhibiting key genes, these findings remain at an early preclinical stage. Funding for the study was provided by the Sky Foundation alongside National Institutes of Health grants P30CA016087 and R01CA245005.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.